PetCaseFinder

Peer-reviewed veterinary case report

What causes blood clots in dogs with immune-mediated hemolytic anemia

By Hamzianpour, Negar & Chan, Daniel L·Published in Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001)·2016·Department of Clinical Science and Services, United Kingdom·View original on PubMed

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: Thromboelastographic assessment of the contribution of platelets and clotting proteases to the hypercoagulable state of dogs with immune-mediated hemolytic anemia.

Species:
dog

Plain-English summary

A group of 27 dogs with immune-mediated hemolytic anemia (IMHA) were tested for blood clotting issues, as these dogs often have a higher risk of blood clots. The tests showed that about 70% of the dogs had signs of increased clotting, with many showing that their platelets were particularly reactive. This suggests that in some cases, using medications to reduce platelet activity might help manage the risk of clotting in these dogs. Further research is needed to confirm these findings and improve treatment options.

People also search for: dog IMHA treatment · immune-mediated hemolytic anemia dog symptoms · anti-platelet medication for dogs

Abstract

BACKGROUND: Hypercoagulability is a well-known feature of canine immune-mediated hemolytic anemia (IMHA) and is believed to increase the risk of thrombosis. This study was undertaken to differentiate the relative contribution of platelets and clotting proteases to this hypercoagulability using thromboelastography (TEG). STUDY DESIGN: Retrospective observational study. METHODS: Thromboelastograms from 27 dogs with IMHA were retrospectively evaluated. Standard TEG parameters (R, K, α, MA), the G value, and the novel parameter delta (Δ) were determined. Hypercoagulability was attributed to the platelet component of hemostasis when there was an increased G value with a normal Δ value. KEY FINDINGS: Nineteen of 27 dogs (70.4%) had ≥ 2 TEG variables suggestive of hypercoagulability, 18 (66.7%) had a hypercoagulable G value, and 11 (40.7%) had a hypercoagulable Δ value. Ten of 27 (37%) samples met the criteria for platelet hypercoagulability. SIGNIFICANCE: Our report documents the derivation and application of the Δ value to differentiate enzymatic from platelet hypercoagulability. Further studies are required to validate the use of these TEG variables in this manner. The hypercoagulable tendency in dogs with IMHA is complex and multifactorial, and in some dogs this hypercoagulability may be attributed primarily to platelet hyper reactivity. Our findings may support the use of anti-platelet drugs in some dogs with IMHA.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/25918856/